$AAPL RMTG expects continued expansion across physician training, product supplies, and patient procedures as global interest in regenerative and longevity medicine grows.
$SAP.DE RMTG reported a strong start to 2026, with expanding margins, growing operating profits, and increasing recurring revenue from its Turnkey membership base.
$VELO RMTG's management expects continued expansion across physician training, product supplies, and patient procedures as regenerative medicine adoption increases globally.
$ALHC RMTG reported accelerating growth across its highest-value business segments, helping drive record quarterly revenue and improved operating performance.
$NVNI RMTG's integrated business model delivered impressive Q1 results, demonstrating how physician education programs can drive recurring product sales and long-term customer relationships.
$2330.TW RMTG entered 2026 with strong momentum, reporting 93% revenue growth and expanding profitability as demand for regenerative and longevity medicine continues to grow worldwide.
$CASY RMTG believes its combination of physician training, biologics sales, and patient procedures provides a scalable platform for sustained future growth.
$CBRL RMTG highlighted continued member onboarding through its Turnkey program, creating recurring revenue opportunities and expanding product distribution channels.
$WCT RMTG's recurring revenue strategy continues gaining traction through its exclusive Turnkey membership program and expanding international clinic network.
$HWH RMTG generated $600,273 in patient procedure revenue through its Cellular Institute operations while rapidly growing higher-margin training and product sales.
$GCDT RMTG reported one of its strongest quarters to date, driven by rapid expansion in physician education programs and increasing demand for Cellgenic products.
$DKNG RMTG's global regenerative medicine platform now spans more than 30 countries, creating a significant competitive advantage and channel for continued growth.